



Spirea granted UK patent on its high drug-to-antibody ratio ADC platform technology

Cambridge, UK, 05 September 2022: Spirea Limited, a biopharmaceutical company developing a new generation of Antibody Drug Conjugate (ADC) therapeutics, has announced that it has been granted UK patent no GB2594753 entitled "Antibody-Drug Conjugates". The patent provides broad coverage of the company's core ADC linker platform technology. Spirea's novel linker enables more cytotoxic drug to be attached to a targeting antibody resulting in the delivery of more drug payload to the target cancer cell. This allows for the development of stable and tailored ADCs incorporating a variety of drug payloads at varying levels of potency and with different modes-of-action resulting in cancer therapeutics with significantly improved efficacy and safety profiles.

Dr Myriam Ouberai, Chief Executive Officer at Spirea, commented: *"This patent grant allows Spirea to build a strong pipeline of highly differentiated ADCs incorporating a range of tumour-targeting antibodies, drug payload modes-of-action and drug-to-antibody ratios optimised to suit specific indications and patient populations. It also gives us the opportunity to partner with biotech and pharmaceutical companies on ADC programmes utilising novel targets and novel/repurposed small molecule payloads or to rescue existing clinical ADC programmes that have failed in development, due to poor safety-efficacy profiles."*

For further information about Spirea, please visit: www.spirea.co.uk

ENDS

About Spirea www.spirea.co.uk

Spirea has developed an exciting and flexible new approach to building ADCs that allows more drug payload to be specifically directed to the target tumour cell. This results in an increase in therapeutic effect whilst substantially reducing debilitating side-effects. By delivering the right amount of the right drug to the right cells, Spirea's proprietary technology will unlock a new generation of accessible, powerful and well-tolerated medicines for the treatment of a wide range of cancers.

Spirea will use its revolutionary technology to build a pipeline of innovative ADC therapeutics. As well as developing its own drugs, the company plans to collaborate with partners on new programmes and to revive pre-existing preclinical and clinical-stage assets that have failed because of narrow therapeutic index.